Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Recommendation of “Buy” from Analysts

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been given a consensus rating of “Buy” by the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $49.40.

SLP has been the subject of several analyst reports. KeyCorp raised their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. Stephens assumed coverage on Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock. BTIG Research lowered their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Finally, StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $31.76, for a total transaction of $635,200.00. Following the transaction, the director now directly owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 19.40% of the company’s stock.

Hedge Funds Weigh In On Simulations Plus

Hedge funds and other institutional investors have recently made changes to their positions in the stock. First Horizon Advisors Inc. grew its holdings in Simulations Plus by 82.6% during the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock valued at $26,000 after purchasing an additional 370 shares during the period. nVerses Capital LLC raised its stake in shares of Simulations Plus by 1,100.0% in the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after buying an additional 1,100 shares during the period. Quantbot Technologies LP purchased a new position in shares of Simulations Plus during the 3rd quarter valued at $59,000. US Bancorp DE grew its stake in shares of Simulations Plus by 37.0% during the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock worth $159,000 after acquiring an additional 1,343 shares during the period. Finally, Pitcairn Co. increased its holdings in Simulations Plus by 9.1% in the 3rd quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock worth $211,000 after acquiring an additional 549 shares during the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Simulations Plus Price Performance

Shares of Simulations Plus stock opened at $34.32 on Friday. The company’s 50 day moving average price is $30.46 and its two-hundred day moving average price is $32.66. The firm has a market capitalization of $689.49 million, a P/E ratio of 85.80 and a beta of 0.80. Simulations Plus has a fifty-two week low of $24.00 and a fifty-two week high of $51.22.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.